Xarelto® Rivaroxaban The first oral direct factor Xa inhibitor - ppt download
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association
Transitioning Between Anticoagulants Continuous Infusion Unfractionated Heparin (UFH) SC LMWH or Fondaparinux Rivaroxaban (Xarel
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) - PDF Free Download
Apixaban starting dose after 1 week LMWH therapy (PE or DVT)? | ResearchGate
Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week - ScienceDirect
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons | The BMJ
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology | Revista Española de Cardiología
Time for a change? Switching anticoagulants in patients with AF or VTE | Thrombosis Adviser
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials -
Dose of XARELTO for Switching From Another Anticoagulant During Initial DVT or PE Treatment
Updated Guidelines on Outpatient Anticoagulation | AAFP
Anticoagulants | Health Navigator NZ
Cureus | Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study
Guidance on Converting Between Anticoagulants
Oral anticoagulants in the management of venous thromboembolism | Nature Reviews Cardiology
Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar - ScienceDirect
How to switch from rivaroxaban to LMWH? | Download Scientific Diagram
Transition of Anticoagulants 2014
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism | Thrombosis Journal | Full Text
Care Transitions in Anticoagulation Management for Patients With Atrial Fibrillation: An Emphasis on Safety | Ochsner Journal
